Penn spinout Vivodyne closed a $38 million seed funding round led by Khosla Ventures.
Vivodyne is a biotech startup that uses clinically predictive AI to help identify therapeutic targets and predict a patient’s response to a drug by testing it on lab-grown human organ tissues.
The company was founded by Dan Huh, PhD, Associate Professor of Bioengineering at Penn, and Andrei Georgescou, PhD, who worked in Huh’s research lab and is now the CEO of Vivodyne.
According to Georgescu, as Vivodyne continues to grow, the overarching goal is to turn the company into the biological equivalent of a “large-scale data center” that allows scientists access to unprecedented capabilities for researching human disease.
Read more here: